Skip to main content
. 2020 Apr 13;12(7):6276–6291. doi: 10.18632/aging.103023

Figure 3.

Figure 3

Elevated ALKBH1 level reduced 6mA DNA level in human aortic smooth muscle cells (HASMCs). (A–C) Representative western blot and quantification of N6AMT1 and ALKBH1 protein levels in HASMCs treated with various concentrations of angiotensin II (Ang II) or endothelin-1 (ET1) for 72 h. GAPDH was the internal control. (D, E) Global 6mA level measured by ELISA assay in Ang II- or ET1–treated HASMCs. (F, G) ALKBH1 mRNA level by RT-qPCR assay (F) and global m6A level by ELISA analysis (G) in Ang II- or ET1–treated HASMCs with siRNA-Control (Si-CN) or siRNA-ALKBH1 transfection. Data are mean ± SD (n= 4/group) and were analyzed by one-way ANOVA, followed by Bonferroni’s multiple comparison test. *P<0.05, **P<0.01 vs the control of Ang II or ET-1. #P<0.05 vs Si-CN and Ang II or ET1 treatment for F and G.